Chen Xiaqin, He Zhijie, Zhao Caiqing, Wu Kaini, Zhu Qi, Fu Yunfeng, Pan Yating, Fan Yuanping, Yang Sicheng, Zeng Yonghua, Luo Shicheng, Liu Lihua, Du Fan, Zhou Xiaodong
Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Sci Rep. 2025 Mar 5;15(1):7788. doi: 10.1038/s41598-025-91265-9.
In patients with gastric cancer (GC), metastatic progression through the lymphatic, haematogenous, peritoneal, and ovarian routes is the ultimate cause of death. We developed a nomogram to estimate cancer-specific survival (CSS) in patients with T1 gastric cancer based on log odds of positive lymph nodes (LODDS). A total of 2,221 patients from the Surveillance, Epidemiology, and End Results (SEER) database were split into training and internal validation cohorts, while an external validation cohort included 165 patients from our hospital. Multivariate Cox regression analysis revealed that age, sex, tumour size, LODDS score, and M stage were independent prognostic factors for CSS. The LODDS outperformed the N stage and positive lymph node (PLN) count in terms of predictive ability and is recognised as an independent prognostic factor for nomogram construction. In the training and internal and external validation sets, the 1-year AUCs of the columniogram were 0.732, 0.672, and 0.719, respectively. The 3-year AUCs were 0.705, 0.692, and 0.638, respectively. The 5-year AUCs were 0.726, 0.698, and 0.713, respectively, indicating good predictive power. The calibration curve revealed that the predicted survival rate was consistent with the actual survival rate in the three groups. The ROC and DCA demonstrated that the nomogram has more potential in predicting prognosis than the existing AJCC staging system. We constructed and validated a novel nomogram leveraging LODDS, which effectively estimates the CSS at 1, 3, and 5 years for individuals with gastric cancer.
在胃癌(GC)患者中,通过淋巴、血行、腹膜和卵巢途径发生的转移进展是最终的死亡原因。我们基于阳性淋巴结对数优势(LODDS)开发了一种列线图,以估计T1期胃癌患者的癌症特异性生存(CSS)。来自监测、流行病学和最终结果(SEER)数据库的2221例患者被分为训练队列和内部验证队列,而外部验证队列包括我院的165例患者。多变量Cox回归分析显示,年龄、性别、肿瘤大小、LODDS评分和M分期是CSS的独立预后因素。在预测能力方面,LODDS优于N分期和阳性淋巴结(PLN)计数,并且被认为是列线图构建的独立预后因素。在训练集、内部验证集和外部验证集中,列线图的1年AUC分别为0.732、0.672和0.719。3年AUC分别为0.705、0.692和0.638。5年AUC分别为0.726、0.698和0.713,表明具有良好的预测能力。校准曲线显示,三组的预测生存率与实际生存率一致。ROC和DCA表明,该列线图在预测预后方面比现有的AJCC分期系统更具潜力。我们构建并验证了一种利用LODDS的新型列线图,该列线图可有效估计胃癌患者1年、3年和5年的CSS。